Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Inclusion Criteria:

• Males or females, aged ≥ 18 years at time of consent.

• Have a diagnosis of Psoriatic Arthritis (PSA, by any criteria) of ≥ 6 months duration.

• Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at time ofscreening.

• Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)

• May not have axial involvement alone

• Concurrent treatment allowed with methotrexate, leflunomide, or sulfasalazine

• Have ≥ 3 swollen AND ≥ 3 tender joints.

• Males & Females must use contraception

• Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low doseoral corticosteroids allowed.

Exclusion Criteria:

• Pregnant or breast feeding.

• History of allergy to any component of the investigational product.

• Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.

• Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF)blocker